Citations

Showing 10 of 108094 citations.

Metabolome-wide association study on ABCA7 indicates a role of ceramide metabolism in Alzheimer’s disease
Dehghan, Abbas , Pinto, Rui , Karaman, İbrahim , Huang, Jian , Durainayagam, Brenan R., Ghanbari, Mohsen , Nazeer, Areesha , Zhong, Qi , Whiley, Luke , Mustafa, Rima , Solomon, Alina , Ngandu, Tiia , Kanekiyo, Takahisa , Aikawa, Tomonori , Radulescu, Carola I. , Graça, Gonçalo , Camuzeaux, Stéphane , Kaluarachchi, Manuja , Holmes, Elaine , Griffin, Julian L. , Whiley, Luke , Mustafa, Rima , Kanekiyo, Takahisa , Aikawa, Tomonori , Barnes, Samuel J , Chekmeneva, Elena , Kaluarachchi, Manuja R , Holmes, Elaine , Matthews, Paul M , Elliott, Paul , Zhong, Qi , Liggi, Sonia , Kivipelto, Miia , Lewis, Matthew R , Ikram, M. Arfan , Tzoulaki, Ioanna , Matthews, Paul M.

Mayo Clinic

Proceedings of the National Academy of Sciences | October 21, 2022 | Volume: 119 | Issue: 43 | Pages: No page available

10.1073/pnas.2206083119 | PMID 36269859 Get It

Genome-wide association studies (GWASs) have identified genetic loci associated with the risk of Alzheimer’s disease (AD), but the molecular mechanisms by which they confer risk are largely unknown. We conducted a metabolome-wide association study (MWAS) of AD-associated loci from GWASs using untargeted metabolic profiling (metabolomics) by ultraperformance liquid chromatography–mass spectrometry (UPLC-MS). We identified an association of lactosylceramides (LacCer) with AD-related single-nucleotide polymorphisms (SNPs) in ABCA7 ( P = 5.0 × 10 −5 to 1.3 × 10 −44 ). We showed that plasma LacCer concentrations are associated with cognitive performance and genetically modified levels of LacCer are associated with AD risk. We then showed that concentrations of sphingomyelins, ceramides, and hexosylceramides were altered in brain tissue from Abca7 knockout mice, compared with wild type (WT) ( P = 0.049–1.4 × 10 −5 ), but not in a mouse model of amyloidosis. Furthermore, activation of microglia increases intracellular concentrations of hexosylceramides in part through induction in the expression of sphingosine kinase, an enzyme with a high control coefficient for sphingolipid and ceramide synthesis. Our work suggests that the risk for AD arising from functional variations in ABCA7 is mediated at least in part through ceramides. Modulation of their metabolism or downstream signaling may offer new therapeutic opportunities for AD.
Synthesis of reactive copolymers with peroxide functionality for cross‐linking water‐soluble polymers
Serdiuk, Vitalii , Shevchuk, Oleh , Kovalenko, Tetiana , Bukartyk, Natalya, Tokarev, Viktor , Bukartyk, N. M. , Kovalenko, Tetiana

Mayo Clinic

Journal of Applied Polymer Science | October 21, 2022 | Volume: 140 | Issue: 1 | Pages: No page available

10.1002/app.53254 Get It

AbstractA series of reactive copolymers with peroxide functionality (RCPFs) were synthesized via radical copolymerization of monomer mixtures in an organic solvent comprised of a peroxide monomer 5‐(tert‐butyl peroxy)‐5‐methylhex‐1‐en‐3‐yne, acrylamide, maleic anhydride, and butyl methacrylate. Peroxide functionality allows the RCPFs to initiate a variety of radical processes, including cross‐linking of organic polymers. Hydrophilic monomer subunits (acrylamide and maleic anhydride) within the RCPF macromolecules promote cross‐linking of water‐soluble polymers. We aimed to investigate RCPF comonomer ratio and its effects on copolymerization kinetics and composition, as well as physico‐chemical and colloidal properties. We also evaluated and characterized the kinetic parameters of the thermal decomposition of peroxide moieties in the synthesized RCPF. Findings revealed that RCPF possessed surface‐active properties and reduced surface tension at its aqueous solution–air interface. The data indicated that the decomposition process complied with the first‐order kinetics, and complex thermal analysis confirmed the presence of peroxide moieties. RCPFs' ability to cross‐link water‐soluble polymers was demonstrated on poly(acrylamide) and poly(vinyl alcohol).
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study
Aldoss, Ibrahim , Yin, Jun , Wall, Anna, Mrózek, Krzysztof , Liedtke, Michaela , Claxton, David F. , Appelbaum, Frederick R. , Erba, Harry P. , Litzow, Mark R. , Tallman, Martin S. , Stone, Richard M. , Luger, Selina M. , Erba, Harry Paul , Litzow, Mark R. , Larson, Richard A , Advani, Anjali S , Claxton, David F , Aldoss, Ibrahim , Foster, Matthew C , Larson, Richard A. , Advani, Anjali S. , Stock, Wendy

Mayo Clinic

Blood Advances | October 21, 2022 | Volume: 7 | Issue: 2 | Pages: 196-204

10.1182/bloodadvances.2022007791 | PMID 36269846 Get It

Abstract Asparaginase is a key component of pediatric-inspired regimens in young adults with acute lymphoblastic leukemia (ALL). Truncation of asparaginase therapy is linked to inferior outcomes in children with ALL. However, a similar correlation in adults is lacking. Here, we studied the prevalence and risk factors associated with pegylated (PEG)-asparaginase discontinuation in young adults with ALL treated on the US intergroup Cancer and Leukemia Group B (CALGB) 10403 study and examined the prognostic impact of early discontinuation (ED) (defined as <4 of 5 or 6 planned doses) on survival outcomes. The analysis included 176 patients who achieved complete remission and initiated the delayed intensification (DI) cycle. The median number of PEG-asparaginase doses administered before DI was 5 (range, 1-6), with 57 (32%) patients with ED. The ED patients were older (median, 26 vs 23 years; P = .023). Survival was apparently lower for ED patients compared with those receiving ≥4 doses, but this finding was not statistically significant (hazard ratio [HR], 1.82; 95% confidence interval [CI], 0.97-3.43; P = .06), with corresponding 5-year overall survival (OS) rates of 66% and 80%, respectively. In patients with standard-risk ALL, the ED of PEG-asparaginase adversely influenced OS (HR, 2.3; 95% CI, 1.02-5.22; P = .04) with a trend toward inferior event-free survival (EFS) (HR, 1.84; 95% CI, 0.92-3.67; P = .08). In contrast, there was no impact of early PEG-asparaginase discontinuation on OS (P = .64) or EFS (P = .32) in patients with high-risk disease based on the presence of high-risk cytogenetics, Ph-like genotype, and/or high white blood cell count at presentation. In conclusion, early PEG-asparaginase discontinuation is common in young adults with ALL and may adversely impact survival of patients with standard-risk ALL.
Lateral medullary infarction presenting as high‐grade heart block
Klarich, Kyle W. , Benarroch, Eduardo E. , Toledano, Michel M., Ward, Robert C. , DeSimone, Christopher V.

Mayo Clinic

Pacing and Clinical Electrophysiology | October 21, 2022 | Volume: 46 | Issue: 6 | Pages: 498-500

10.1111/pace.14608 | PMID 36268813 Get It

A review of transthyretin cardiac amyloidosis
Leoni, Juan , Chirilă, Răzvan M. , Jhawar, Nikita , Moreno, Juan Carlos Leoni, Chirilă, Răzvan , Leoni, Juan Carlos

Mayo Clinic

Romanian Journal of Internal Medicine | October 21, 2022 | Volume: 61 | Issue: 1 | Pages: 28-34

10.2478/rjim-2022-0018 | PMID 36278951 Get It

Abstract Transthyretin cardiac amyloidosis is a progressive disease known to cause heart failure, conduction anomalies, and arrythmias. Due to poor outcomes and mortality from severe cardiomyopathy, prevalence and incident rates are often underreported. As global longevity is increasing and rates of amyloidosis are also increasing, there is a need to improve diagnostic and therapeutic interventions. Previously, symptom management and transplantation were the mainstay of treatment for heart failure symptoms, but studies using RNAi and siRNA technologies have shifted the paradigm of therapeutic strategy in amyloid cardiomyopathy management. Additionally, early detection and clinical monitoring with numerous imaging and non-imaging techniques are being increasingly investigated. Here, we review the epidemiology, pathophysiology, diagnosis, and management of transthyretin amyloid cardiomyopathy.
Diagnosis, symptoms, and treatment knowledge of aberrant right subclavian artery in followers of a social media group
Olson, Caroline G. , Valery, Jose R. , Bi, Yan , Pocchetino, Alberto, Olson, Caroline , Cortés, Pedro , Stancampiano, Fernando F. , Harris, Dana M.

Mayo Clinic

Romanian Journal of Internal Medicine | October 21, 2022 | Volume: 61 | Issue: 1 | Pages: 3-5

10.2478/rjim-2022-0019 | PMID 36278963 Get It

Two New Phenomena Associated With Filler Injection
Cotofana, Sebastian , Velthuis, Peter J. , Cotofana, Sebastian , Frank, Konstantin , Schelke, Leonie

Mayo Clinic

Aesthetic Surgery Journal | October 21, 2022 | Volume: 43 | Issue: 2 | Pages: NP134-NP135

10.1093/asj/sjac271 | PMID 36268611 Get It

Resolution of atlanto-occipital cyst with conservative management: A case report and review of the literature
Rivas, Gabriella , Hurdle, Mark Friedrich B., Chen, Selby , Rivas, Gabriella A., Hurdle, Mark, Biase, Gaetano De , Domingo, Ricardo A. , Fox, W Christopher

Mayo Clinic

Surgical Neurology International | October 21, 2022 | Volume: 13 | Issue: No issue available | Pages: 478

10.25259/sni_841_2022 | PMID 36324942 Get It

Background: Spinal synovial cysts are cystic dilatations of synovial sheaths that extrude into the spinal canal. Despite their generally benign behavior, they can cause severe symptoms due to compression of neural structures. They are most commonly found in the lumbar spine and are rare in the cervical region, especially at the atlanto-occipital junction. Case Description: A 65-year-old presented with neck pain and headaches. The magnetic resonance imaging (MRI) revealed a degenerative cyst within the anterior foramen magnum causing anterior spinal cord and brainstem compression. Multiple surgical treatment options were discussed, and he was prescribed methylprednisolone and immobilization of his cervical spine with a rigid collar. One month later, the patient reported dramatic improvement of his symptoms, and no surgery was performed. One year later, his pain had remained much improved with the continued use of the collar and pain management (i.e., using anti-inflammatories and muscle relaxants). The 1-year follow-up MRI showed the atlanto-occipital cyst compressing the cervicomedullary junction had completely resolved along with the brainstem compression. Conclusion: A 65-year-old presented with myelopathy attributed to a large anterior foramen magnum atlanto-occipital cyst compressing the cord. Conservative management for 1 month with a rigid cervical collar and steroids resulted in marked neurological improvement; at 1 year follow-up, the patient was markedly improved with an MR that demonstrated spontaneous cyst regression.
Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials
Lee, Scott D. , Lee, Wan‐Ju , Griffith, Jenny, Wallace, Kori, Berg, Sofie, Liao, Xiaomei, Loftus, Edward V. , Louis, Édouard , Lee, Scott D , Loftus, Edward V , Louis, Edouard , Peyrin‐Biroulet, Laurent , Ghosh, Subrata , Panés, Julián

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 21, 2022 | Volume: 57 | Issue: 5 | Pages: 496-508

10.1111/apt.17242 | PMID 36266762 Get It

SummaryBackgroundCrohn's disease has a substantial negative impact on health‐related quality of life (HRQoL).AimTo examine the effects of risankizumab on HRQoL in Crohn's diseaseMethodsWe analysed data from patients with Crohn's disease from 12‐week induction trials ADVANCE (N = 850) and MOTIVATE (N = 569) with risankizumab 600 mg or 1200 mg intravenous (IV) versus placebo IV and a 52‐week maintenance trial FORTIFY (N = 462) with risankizumab 180 or 360 mg subcutaneous (SC) versus placebo SC. Outcomes included Inflammatory Bowel Disease Questionnaire (IBDQ), Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F), 36‐item Short Form Health Survey (SF‐36), EuroQol 5‐Dimension‐5‐Level (EQ‐5D‐5L) and work productivity. The mean change and percentages of patients achieving clinically meaningful improvement in all outcomes were determined at weeks 12 and 52.ResultsAt week 12, more patients in the risankizumab 600 or 1200 mg groups achieved IBDQ response than with placebo (ADVANCE: 70.2%, 75.5% vs. 47.8%, p ≤ 0.001; MOTIVATE: 61.7%, 68.5% vs. 48.2%, p ≤ 0.01) and FACIT‐F response (ADVANCE: 51.3%, 48.0% vs. 35.7%, p ≤ 0.01; MOTIVATE: 44.2%, 49.1% vs. 33.7%, p < 0.05). These improvements persisted at week 52 with risankizumab maintenance treatment. Similar trends were observed for SF‐36 physical and mental component summary scores, EQ‐5D‐5L and activity impairment within work productivity measures.ConclusionsRisankizumab induction therapy (600 or 1200 mg IV) led to clinically meaningful improvements in disease‐specific and general patient‐reported outcomes, including fatigue, in patients with moderate to severe Crohn's disease. These improvements were sustained after 52 weeks of risankizumab (180 or 360 mg SC) maintenance therapy.
Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer
Oswalt, Cameron , Liu, Yingzhou , Pang, Herbert , Wang, Xiaofei , Crawford, Jeffrey , Crawford, Jeffrey , Liu, Yingzhou, Le‐Rademacher, Jennifer

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | October 21, 2022 | Volume: 13 | Issue: 6 | Pages: 2650-2660

10.1002/jcsm.13095 | PMID 36268548 Get It

AbstractBackgroundWeight loss (WL) has been associated with shorter survival in patients with advanced cancer, while obesity has been associated with longer survival. Integrating body mass index (BMI) and WL provides a powerful prognostic tool but has not been well‐studied in lung cancer patients, particularly in the setting of clinical trials.MethodsWe analysed patient data (n = 10 128) from 63 National Cancer Institute sponsored advanced non‐small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) trials. Risk matrices were created using BMI and WL percentage, which were divided into ‘grades’ based on median survival. Relationships between survival, BMI and WL percentage were examined using Kaplan–Meier estimators and Cox proportional hazards (PH) models with restricted cubic splines.ResultsFor NSCLC, a twofold difference was noted in median survival between the BMI > 28 and WL ≤ 5% group (13.5 months) compared with the BMI < 20 and WL > 5% group (6.6 months). These associations were less pronounced in SCLC. Kaplan–Meier curves showed significant survival differences between grades for both NSCLC and SCLC (log‐rank, P < 0.0001). In Stage IV NSCLC, Cox PH analyses with restricted cubic splines demonstrated significant associations between BMI and survival in both WL ≤ 5% (P = 0.0004) and >5% (P = 0.0129) groups, as well as in WL > 5% in Stage III (P = 0.0306). In SCLC, these relationships were more complex.ConclusionsBMI and WL have strong associations with overall survival in patients with advanced lung cancer, with a greater impact seen in NSCLC compared with SCLC. The integration of a BMI/WL grading scale may provide additional prognostic information and should be included in the evaluation of therapeutic interventions in future clinical trials in advanced lung cancer.